阻塞性睡眠呼吸暂停低通气综合征与成纤维细胞生长因子21

doi:10.6040/j.issn.1673-3770.0.2016.319

摘要/Abstract

摘要： 阻塞性睡眠呼吸暂停低通气综合征(OSAHS)发病率逐年升高,已经成为危害人类健康的主要疾病之一。迄今为止,OSAHS 的发病机制尚未阐明。成纤维细胞生长因子21(FGF21)是参与糖脂代谢的一种重要蛋白质。近年来大量的研究显示FGF21与OSAHS的发生发展有密切的联系。本文就近些年OSAHS与FGF21的相关研究进行简要综述。

关键词: 睡眠呼吸暂停低通气综合征, 能量代谢, 成纤维细胞生长因子21, 糖脂代谢

Abstract: The prevalence of OSAHS has been dramatically increasing during the last decade, which has become one of the major diseases that endangers human health. The pathogenesis of OSAHS is not yet fully clear. Some studies have shown that FGF21 is closely linked with OSAHS. The correlation between FGF21 and OSAHS will be discussed in this chapter.

Key words: Fibroblast growth factor 21, Glucose and lipid metabolism, Energy metabolism, Obstructive sleep apnea hypopnea syndrome

中图分类号:

R766.7

梁小红,李艳, 李翀. 阻塞性睡眠呼吸暂停低通气综合征与成纤维细胞生长因子21[J]. 山东大学耳鼻喉眼学报, 2016, 30(5): 81-84.

LIANG Xiaohong, LI Yan, LI Chong. Obstructive sleep apnea hypopnea syndrome and Fibroblast growth factor 21.[J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(5): 81-84.

参考文献

[1] Nishimura T, Nakatake Y, Konishi M, et al. Identification of a novel FGF, FGF-21, preferentially expressed in the liver[J]. Biochim Biophys Acta, 2000, 1492(1):203-206.
[2] Iglesias P, Selgas R, Romero S, et al. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21[J]. Eur J Endocrinol, 2012, 167(3):301-309.
[3] Nies V J, Sancar G, Liu W, et al. Fibroblast growth factor signaling in metabolic regulation[J]. Front Endocrinol(Lausanne), 2015, 6:193.
[4] Indrakusuma I, Sell H, Eckel J. Novel mediators of adipose tissue and muscle crosstalk[J]. Curr Obes Rep, 2015, 4(4):411-417.
[5] Owen B M, Mangelsdorf D J, Kliewer S A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21[J]. Trends Endocrinol Metab, 2015, 26(1):22-29.
[6] Zhao Y, Dunbar J D, Kharitonenkov A. FGF21 as a therapeutic reagent[J]. Adv Exp Med Biol, 2012, 728(2):214-228.
[7] So W Y, Leung P S. Fibroblast growth factor 21 as an emerging therapeutic target for Type 2 diabetes mellitus[J]. Med Res Rev, 2016, 36(4):672-704.
[8] Chau M D, Gao J, Yang Q, et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway[J]. Proc Natl Acad Sci U S A, 2010, 107(28):12553-12558.
[9] 芮欣忆, 阮晓楠,周先锋,等.上海市浦东新区20~74岁居民超重、肥胖、中心性肥胖的现况调查及流行特征[J].中华内分泌代谢杂志, 2016, 32(3):206-212. RUI Xinyi, RUAN Xiaonan, ZHOU Xianfeng, et al. Prevalence and epidemic characteristic of overweight, obesity, and central obesity in Shanghai Pudong New[J]. Chin J Endocrinol Metab, 2016, 32(3):206-212.
[10] 中华医学会呼吸病学会睡眠呼吸障碍学组,阻塞性睡眠呼吸暂停低通气综合征诊治指南(2011年修订版)[J].中华结核和呼吸杂志,2012,35(1):9-12. Chinese Medical Association of respiratory disease sleep respiratory disorder group, Clinical Practice Guidelines on traetment of obstructive sleep apnea sydrome[J]. Chin J Tuber Resp Dis, 2012, 35(1):9-12.
[11] Parekh R, Green E, Majeed A. Obstructive sleep apnoea: quantifying its association with obesity and snoring[J]. Prim Care Respir J, 2012, 21(4):361-362.
[12] Romero-Corral A, Caples S M, Lopez-Jimenez F, et al. Interactions between obesity and obstructive sleep apnea: implications for treatment[J]. Chest, 2010, 137(3):711-719.
[13] Giralt M, Gavalda-Navarro A, Villarroya F. Fibroblast growth factor-21, energy balance and obesity[J]. Mol Cell Endocrinol, 2015, 418:66-73.
[14] Fisher F M, Chui P C, Antonellis P J, et al. Obesity is a fibroblast growth factor 21(FGF21)-resistant state[J]. Diabetes, 2010, 59(11):2781-2789.
[15] Reinehr T, Woelfle J, Wunsch R, et al. Fibroblast growth factor 21(FGF-21)and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis[J]. J Clin Endocrinol Metab, 2012, 97(6):2143-2150.
[16] Zhang J, Li Y. Fibroblast growth factor 21 analogs for treating metabolic disorders[J]. Front Endocrinol(Lausanne), 2015, 6:168.
[17] Hui P, Jia S, Ma W, et al. The clinical significance and changes of serum tumor necrosis factor and plasma endothelium in patients with OSAHS associated Type 2 diabetes mellites[J]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2016, 30(3):217-219, 225.
[18] Xu J, Long Y S, Gozal D, et al. Beta-cell death and proliferation after intermittent hypoxia: role of oxidative stress[J]. Free Radic Biol Med, 2009, 46(6):783-790.
[19] Fan H, Sun X, Zhang H, et al. Effect of metformin on fibroblast growth factor-21 levels in patients with newly diagnosed Type 2 diabetes[J]. Diabetes Technol Ther, 2016, 18(3):120-126.
[20] Adams A C, Halstead C A, Hansen B C, et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys[J]. PLoS One, 2013, 8(6):e65763.
[21] Mu J, Pinkstaff J, Li Z, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents[J]. Diabetes, 2012, 61(2):505-512.
[22] Lin Z, Tian H, Lam K S, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice[J]. Cell Metab, 2013, 17(5):779-789.
[23] Anker S D, von Haehling S, Germany R. Sleep-disordered breathing and cardiovascular disease[J]. Indian Heart J, 2016, 68(1):69-76.
[24] Cheng P, Zhang F, Yu L, et al. Physiological and pharmacological roles of FGF21 in cardiovascular diseases[J]. J Diabetes Res, 2016, 2016:1540267.
[25] Chow WS, Xu A, Woo YC, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors[J]. Arterioscler Thromb Vasc Biol, 2013, 33(10):2454-2459.
[26] Jin L, Lin Z, Xu A. Fibroblast growth factor 21 protects against atherosclerosis via fine-tuning the multiorgan crosstalk[J]. Diabetes Metab J, 2016, 40(1):22-31.
[27] Lin Z, Pan X, Wu F, et al. Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice[J]. Circulation, 2015, 131(21):1861-1871.
[28] Cuevas-Ramos D, Aguilar-Salinas C A. Modulation of energy balance by fibroblast growth factor 21[J]. Horm Mol Biol Clin Investig, 2016.
[29] Hanssen M J, Broeders E, Samms R J, et al. Serum FGF21 levels are associated with brown adipose tissue activity in humans[J]. Sci Rep, 2015, 5:10275.
[30] Takx R, Ishai A, Truong Q A, et al. Supraclavicular Brown adipose tissue FDG uptake and cardiovascular disease[J]. J Nucl Med, 2016, 57(8):1221-1225.

相关文章 15

[1]	王桂芳,李仁高,马青. H-UPPP联合低温等离子舌根射频消融术对OSAHS患者血氧饱和度及动脉血氧分压的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 49-54.
[2]	王磊,李保卫,王刚,刘红丹,韩浩伦,张晓丽,吴玮. 阻塞性睡眠呼吸暂停低通气综合征患者夜间碱反流初步研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(6): 75-79.
[3]	袁钰淇,曹子讷,牛晓欣,谢雨杉,苏永龙,朱思敏,张一彤,刘海琴,任晓勇,施叶雯. 外周血炎症指标在阻塞性睡眠呼吸暂停低通气综合征伴高血压中的临床意义[J]. 山东大学耳鼻喉眼学报, 2023, 37(6): 85-92.
[4]	邢亮,袁钰淇,谢雨杉,苏永龙,牛晓欣,麻莉娜,王子桐,刘海琴,施叶雯,任晓勇. 不同觉醒阈值阻塞性睡眠呼吸暂停低通气患者对血气、糖脂代谢水平的影响[J]. 山东大学耳鼻喉眼学报, 2023, 37(6): 106-111.
[5]	丁龙庆,刘漪鸣,程卓,孙冉,梁辉. 口咽运动治疗成人阻塞性睡眠呼吸暂停低通气综合征的疗效初步观察[J]. 山东大学耳鼻喉眼学报, 2023, 37(6): 153-158.
[6]	陈尚丽,秦涛,陈璇,陈若瑾,唐智. Hcy及其代谢关键酶MTHFR C677T基因多态性与OSAHS患者高血压的相关性研究[J]. 山东大学耳鼻喉眼学报, 2023, 37(4): 126-133.
[7]	李卓君,宋西成,陈秀梅. 阻塞性睡眠呼吸暂停低通气综合征患者的肺功能变化分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(2): 45-50.
[8]	王楠,黄晶,彭涛,冯勃. OSAHS与耳鸣的相关性研究现状[J]. 山东大学耳鼻喉眼学报, 2023, 37(2): 122-127.
[9]	张晓雪,王伟,刘杰,许贞菊,钱永恒,韩敏. 儿童与成人OSAHS患者的口咽部菌群特征及药敏学分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(1): 35-40.
[10]	韩莹莹，李延忠. 阻塞性睡眠呼吸暂停低通气综合征与亚临床动脉粥样硬化[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 126-132.
[11]	杨晰珺,关建，吴海莺. 阻塞性睡眠呼吸暂停低通气综合征与血脂紊乱关系的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(2): 133-138.
[12]	季迪,邓安春. 外科干预对阻塞性睡眠呼吸暂停低通气综合征患者血压影响的系统评价[J]. 山东大学耳鼻喉眼学报, 2020, 34(6): 92-98.
[13]	李晓, 袁英, 李延忠, 王岩, 杨珂, 孙永强, 于学民, 王宁, 王磊. 焦虑抑郁对阻塞性睡眠呼吸暂停低通气综合征患者夜间血压波动的影响[J]. 山东大学耳鼻喉眼学报, 2019, 33(6): 68-71.
[14]	张会芳,杨红珍. 经鼻持续气道正压通气对阻塞性睡眠呼吸暂停低通气[J]. 山东大学耳鼻喉眼学报, 2018, 32(2): 48-51.
[15]	孙娜,陈晓平. 咽喉反流与耳鼻咽喉科疾病[J]. 山东大学耳鼻喉眼学报, 2016, 30(6): 85-89.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed